SCHEMBL2951504

SCHEMBL2951504

Cc1[nH]c2ccccc2c1CN1CC(Nc2nccc(N3CCCCCC3)n2)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 2/20 0.56
MAPT P10636 4/20 0.53
KMT2A Q03164 4/20 0.53
CHIA Q9BZP6 1/20 0.53
HTR1A P08908 2/20 0.44
HRH4 Q9H3N8 4/20 0.43
KDM4E B2RXH2 2/20 0.42
HTT P42858 2/20 0.42
GAA P10253 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
CHRNA7 P36544 1/20 0.41
HCRTR1 O43613 1/20 0.41
HCRTR2 O43614 1/20 0.41
ALDH1A1 P00352 2/20 0.40
POLB P06746 1/20 0.40
MEN1 O00255 2/20 0.39
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPK8 P45983 2/20 0.39
MAPK9 P45984 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1092284 0.81 CXCR4 (0.58) CXCR4HTR1AKDM4EHTTALDH1A1
SCHEMBL1091394 0.79 CXCR4 (0.63) CXCR4HRH4MAPK8MAPK9
SCHEMBL1089573 0.79 CXCR4 (0.85) CXCR4HRH4
SCHEMBL1090977 0.79 CXCR4 (0.62) CXCR4HTR1AHRH4MAPK8MAPK9
SCHEMBL1090774 0.78 CXCR4 (0.56) CXCR4HTR1AHRH4MAPK8MAPK9
SCHEMBL1089675 0.78 CXCR4 (0.58) CXCR4HRH4HCRTR1HCRTR2MAPK8
SCHEMBL1090262 0.77 CXCR4 (0.66) CXCR4KMT2AHRH4LMNAMAPK8
SCHEMBL1090768 0.77 CXCR4 (0.69) CXCR4HRH4
SCHEMBL1091367 0.77 CXCR4 (0.58) CXCR4MAPTKMT2AHRH4HTT
SCHEMBL2950290 0.77 CXCR4 (0.57) CXCR4HRH4HCRTR1HCRTR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-06-21 US disclosed
US-7759336-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-20 US disclosed
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-19 US disclosed
EP-1571146-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof CXCR4, CXCL12, CXCR3 CXCR4 1/4885MAPT 4748/4885KMT2A 3064/4885
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 CXCR4 1/4885MAPT 4748/4885KMT2A 3064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.